Phase 3 N=79 Safety and Efficacy of Remimazolam in ASA III and IV Patients Undergoing Colonoscopy
Colonoscopy
Primary: Success Rates of the Procedure — 27; 0; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=83 Pentoxifylline Treatment in Acute Pancreatitis (AP)
Acute Pancreatitis (AP) · Gallstone Pancreatitis · Alcoholic Pancreatitis
Primary: Change in C-reactive Protein (C-RP) From Admission Baseline at One Week. — 86.2; 75.8; 116.4; 127.2 mg/L — p=0.5796
Phase 3 N=2,250 A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
Influenza, Human
Primary: The Geometric Mean Titer (GMT) Ratio of Each Virus Strain. — 370.0; 311.7; 436.8; 589.1 Geometric Mean Titer
Phase 3 N=658 Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis
Vaginitis
Primary: Clinical Treatment Efficacy Assessed by the Investigator After Thorough Gynaecological Examination and Patient's Interview at End of Treatment Visit — 275; 268; 27; 41…
Phase 3 N=510 Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)
Dermatitis, Atopic
Primary: Time to Onset of Asthma During the Treatment Period — NA; NA months — p==0.991
Phase 3 N=750 Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A
Infections, Streptococcal
Primary: Number of Subjects Reported With Core Fever (Rectal Temperature) Greater Than or Equal to (≥) the Cut-off — 64; 14; 100; 16 Participants
Phase 3 N=135 A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]
Autosomal Dominant Polycystic Kidney Disease （ADPKD)
Primary: Total Kidney Volume — 1812.38; 1878.82; 1934.14; 2214.28 mL
Phase 3 N=94 Adductor Canal Block Versus Femoral Nerve Block for Total Knee Arthroplasty
Arthropathy of Knee
Primary: Mean Distance Ambulated at 24 Hours Post Operatively — 70.2; 48.44 feet
Phase 3 N=200 Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children
Malaria
Primary: Number of Subjects With Serious Adverse Events (SAEs) — 41; 37; 41; 37 Participants
Phase 3 N=291 Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies
Scabies
Primary: Number of Index Subjects Completely Cured of Scabies After a Single Treatment — 30; 20 Participants
Phase 3 N=280 Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies
Scabies
Primary: Number of Index Subjects Completely Cured of Scabies After a Single Treatment — 52; 20 Participants
Phase 3 N=148 Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma
Asthma
Primary: Trough FEV1 After One Week of Treatment, Point Estimate — 2.392; 2.392; 2.303 Liters — p=<0.001
Phase 3 N=600 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine
Infections, Streptococcal
Primary: Number of Subjects With Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations >= 0.20 Microgram Per Milliliter (µg/mL)…
Phase 3 N=40 A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas
Psoriasis Vulgaris
Primary: The Percentage Change in Psoriasis Area and Severity Index (PASI) of the Face Last Observation Carried Forward (LOCF) at End of Treatment — -60.8; -54.2 percentage of…
Phase 3 N=420 A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma
Asthma
Primary: Change From Baseline in Asthma Control Test (ACT) Total Score at Week 12 — 2.8; 3.6 Scores on a Scale — p=0.033